Table 1.
Patient characteristics and comorbidities at baseline
| Period B (all patients receiving ADAew in Period A), N = 300 | ||||
|---|---|---|---|---|
| ADAew/pbo, N = 100 | ADAew/eow, N = 101 | ADAew/ew, N = 99 | Total, N = 300 | |
| Male, n (%) | 44 (44) | 36 (35·6) | 33 (33·3) | 113 (37·7) |
| Female, n (%) | 56 (56) | 65 (64·4) | 66 (66·7) | 187 (62·3) |
| Ethnicity, n (%) | ||||
| White | 81 (81) | 77 (76·2) | 90 (90·9) | 248 (82·7) |
| Black | 13 (13) | 19 (18·8) | 6 (6·1) | 38 (12·7) |
| Othera | 6 (6) | 5 (4·9) | 3 (5·8) | 12 (4·0) |
| Age, years, median (range) | 35 (20–67) | 36 (19–63) | 34 (18–64) | 35 (18–67) |
| BMI, kg m−2, median (range) | 32·6 (17·4–53·5); (N = 99) | 30·5 (18·3–53·4) | 31·5 (20·3–54·5) | 31·6 (17·4–54·5); (N = 299) |
| BMI,b kg m−2; n (%) | ||||
| Normal weight (< 25) | 21 (21·2) | 21 (20·8) | 14 (14·1) | 56 (18·7) |
| Overweight (25 to < 30) | 19 (19·2) | 26 (25·7) | 26 (26·3) | 71 (23·7) |
| Obese (30 to < 40) | 44 (44·4) | 39 (38·6) | 48 (48·5) | 131 (43·8) |
| Morbidly obese (≥ 40) | 15 (15·2) | 15 (14·9) | 11 (11·1) | 41 (13·7) |
| Current nicotine use, n (%) | 54 (54·0) | 65 (64·4) | 59 (59·6) | 178 (59·3) |
| Disease characteristics | ||||
| Hurley stage II, n (%) | 55 (55) | 52 (51·5) | 49 (49·5) | 156 (52·0) |
| Hurley stage III, n (%) | 45 (45) | 49 (48·5) | 50 (50·5) | 144 (48·0) |
| Modified Sartorius score, median (range) | 107 (18–397) | 100 (19–433) | 104 (20–1093) | 159·5 (18–1093) |
| Family history of HS, n (%) | 23 (23) | 21 (21·0) | 29 (29·3) | 73 (24·4) |
| Median disease duration, years (range) | 8·2 (1·1–43·5) | 8·5 (1·1–33·3) | 10·1 (1·0–40·4) | 8·9 (1·0–43·5) |
| HS lesions; mean (SD) | ||||
| AN | 13·1 (9·97) | 12·1 (10·52) | 12·1 (10·14) | 12·5 (10·19) |
| Abscess | 2·8 (3·59) | 2·6 (3·06) | 2·0 (2·61) | 2·4 (3·12) |
| Draining fistula | 4·1 (4·90) | 3·8 (5·11) | 3·6 (4·23) | 3·8 (4·75) |
| Inflammatory nodule | 10·3 (7·96) | 9·7 (9·74) | 10·1 (9·44) | 10·0 (9·05) |
| Daily pain at worst, median (range 0–10) | 4·7 (0–10); (N = 97) | 5·0 (0–10); (N = 100) | 4·4 (0–9·7); (N = 97) | 4·7 (0–10); (N = 294) |
| Prior surgery for HS, n (%) | 16 (16) | 17 (16·8) | 11 (11·1) | 44 (14·7) |
| hsCRP, mg L−1 mean (SD) | 16·4 (19·12); (N = 52) | 17·7 (22·80) | 16·9 (24·82) | 17·0 (22·31); (N = 299) |
pbo, placebo; ADAew, adalimumab every‐week dosing; BMI, body mass index; HS, hidradenitis suppurativa; AN, abscesses and inflammatory nodules; hsCRP, high‐sensitivity C‐reactive protein. a‘Other’ includes Asian [n = 4 (4%) ADAew/pbo; n = 3 (3·0%) ADAew/eow; and n = 7 (2·3%) all ADAew] and other ethnicities than those mentioned in this table and table footnote [n = 1, (1·0%) ADAew/pbo, n = 2, (2·0%) ADAew/eow, n = 2, (2·0%) ADAew/ew, and n = 5, (1·7%) all ADAew]. bMissing data for one patient (ADAew/pbo).